2/18/2009

GlaxoSmithKline paid Synta Pharmaceuticals $10 million related to their development of elesclomol, an experimental treatment that is being tested for late-stage melanoma and prostate cancer. The payment comes after GSK enrolled patients for a Phase III study of the drug, which triggers apoptosis to inhibit cancer.

Related Summaries